U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H34O5
Molecular Weight 402.5238
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Clascoterone

SMILES

CCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(=O)CO

InChI

InChIKey=GPNHMOZDMYNCPO-PDUMRIMRSA-N
InChI=1S/C24H34O5/c1-4-21(28)29-24(20(27)14-25)12-9-19-17-6-5-15-13-16(26)7-10-22(15,2)18(17)8-11-23(19,24)3/h13,17-19,25H,4-12,14H2,1-3H3/t17-,18+,19+,22+,23+,24+/m1/s1

HIDE SMILES / InChI
Molecular Formula C24H34O5
Molecular Weight 402.5238
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Cortexolone 17α-propionate (WINLEVI, BREEZULA) is a steroid belonging to the family of cortexolone derivatives. It is a topical and peripherally selective androgen antagonist. WINLEVI is used for the treatment of acne and has completed Phase II clinical trials and Phase III trials. BREEZULA is used for the treatment of androgenic alopecia and is currently undergoing a Phase II trial in the US.

CNS Activity

CNS Non-penetrant
1040
Curator's Comment: The explanation of peripheral selectivity of cortexolone 17α-propionate could be that it poorly penetrates the blood-brain barrier, thus failing to achieve an adequate concentration in CNS. However, this last hypothesis needs to be confirmed as tissue distribution studies will be performed.

Originator

Approval Year

2020
691
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
BREEZULA

Approved Use

Unknown
Primary
Phase III
665
WINLEVI

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.81 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CLASCOTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
7.65 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CLASCOTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.16 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CORTODOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1.27 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CORTODOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.5 ng/mL
DRUG LABEL
https://www.winlevi-hcp.com/pdf/winlevi-prescribing-information.pdf#page=2
6 g 2 times / day steady-state, topical
dose: 6 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLASCOTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.96 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CLASCOTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
59.86 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CLASCOTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
15.52 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CORTODOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
11.24 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CORTODOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
37.1 ng × h/mL
DRUG LABEL
https://www.winlevi-hcp.com/pdf/winlevi-prescribing-information.pdf#page=2
6 g 2 times / day steady-state, topical
dose: 6 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLASCOTERONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CLASCOTERONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
90.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/33942574/
225 mg 2 times / day multiple, topical
dose: 225 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
CORTODOXONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
11%
DRUG LABEL
https://www.winlevi-hcp.com/pdf/winlevi-prescribing-information.pdf#page=2
CLASCOTERONE plasma
Homo sapiens
Doses

Doses

DosePopulationAdverse events​
1 % 2 times / day multiple, topical
Studied dose
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32348828/
unhealthy, ADOLESCENT|ADULT
Health Status: unhealthy
Age Group: ADOLESCENT|ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/32348828/
Disc. AE: Hair color changes...
AEs leading to
discontinuation/dose reduction:
Hair color changes (grade 2, 0.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32348828/
1 % 2 times / day multiple, topical
Studied dose
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32320027/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/32320027/
Sources:
https://pubmed.ncbi.nlm.nih.gov/32320027/
AEs

AEs

AESignificanceDosePopulation
Hair color changes grade 2, 0.3%
Disc. AE
1 % 2 times / day multiple, topical
Studied dose
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32348828/
unhealthy, ADOLESCENT|ADULT
Health Status: unhealthy
Age Group: ADOLESCENT|ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/32348828/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
Anti-acne drugs in phase 1 and 2 clinical trials.
2017-07
The use of hormonal agents in the treatment of acne.
2016-06
Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream.
2011-07
Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist.
2004
Patents

Patents

US20160303141
1
US9486458
1

Sample Use Guides

In Vivo Use Guide
Cortexolone 17α-propionate 1% cream was applied every 12 hours for 2 weeks in children 9-12 years old with acne.
Route of Administration: Topical
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:48:22 GMT 2025
Edited
by admin
on Wed Apr 02 07:48:22 GMT 2025
Record UNII
XN7MM8XG2M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Clascoterone
USAN   INN  
Official Name English
CB-03-01
Preferred Name English
Clascoterone [WHO-DD]
Common Name English
PREGN-4-ENE-3,20-DIONE, 17,21-DIHYDROXY-, 17-PROPIONATE
Systematic Name English
CLASCOTERONE [USAN]
Common Name English
WINLEVI
Brand Name English
CLASCOTERONE [MI]
Common Name English
clascoterone [INN]
Common Name English
21-Hydroxy-3,20-dioxopregn-4-en-17-yl propanoate
Systematic Name English
PREGN-4-ENE-3,20-DIONE, 21-HYDROXY-17-(1-OXOPROPOXY)-
Systematic Name English
CORTODOXONE 17.ALPHA.-PROPIONATE
Common Name English
CORTEXOLONE 17.ALPHA.-PROPIONATE
Common Name English
CLASCOTERONE [ORANGE BOOK]
Common Name English
BREEZULA
Brand Name English
Code System Code Type Description
ChEMBL
CHEMBL3545016
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
CAS
19608-29-8
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
DAILYMED
XN7MM8XG2M
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
NCI_THESAURUS
C169855
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
FDA UNII
XN7MM8XG2M
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
WIKIPEDIA
Clascoterone
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
USAN
EF-84
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
PUBCHEM
11750009
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
EPA CompTox
DTXSID10471883
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
MERCK INDEX
m12233
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
INN
10891
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
RXCUI
2474340
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
SMS_ID
300000005912
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
DRUG BANK
DB12499
Created by admin on Wed Apr 02 07:48:22 GMT 2025 , Edited by admin on Wed Apr 02 07:48:22 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INHIBITOR
clascoterone cream, 1%, has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4.
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Plasma protein binding of clascoterone is independent of concentrations, in vitro.
BINDING
CYTOCHROME P450 2C8
METABOLIC ENZYME -> INHIBITOR
clascoterone cream, 1%, has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4.
IC50
ANDROGEN RECEPTOR
TARGET -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
clascoterone cream, 1%, has no clinically meaningful effect on the PK of drugs metabolized by CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 or 3A4.
Related Record Type Details
Structure of Clascoterone
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966